Key facts
- It has raised $15.8M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include Shenzhen Capital Group, Ningbo Zhongzhe Investment, Wuhan Grand Pharmaceutical.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Forefront (Pharmaceuticals)
- ·The full record, as it builds
Funding rounds
No funding rounds for Forefront (Pharmaceuticals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Forefront (Pharmaceuticals)
Manufacturer of advanced pharmaceuticals intended to develop generics and innovative medicines for critical diseases. The company offers expertise in complex synthesis, controlled-release formulations, and therapeutic research across oncology, cardiovascular, neurological, and viral conditions, enabling healthcare providers worldwide to access effective, reliable, and affordable treatments.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2014
- Employees
- 17
- Website
- forefrontpharma.com/
- Ownership
- Privately Held (backing)
Forefront (Pharmaceuticals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Forefront (Pharmaceuticals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Forefront (Pharmaceuticals) in its N-PORT filings yet. We sweep new filings monthly.